Navigation Links
AIDS study challenges conventional treatment guidelines for HIV patients

V, totaling more than 2,800 individuals. The first cohort consisted of patients included in three data sources: a) four sites of the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS), a database of real-time clinical care and laboratory data; b) the San Francisco Men's Health Study (SFMHS) and the Research in Access to Care for the Homeless Cohort (REACH). This cohort included approximately 12% female and 35% non- Caucasian participants. The second cohort, which the investigators used to validate their findings in the first group, included participants in the Multicenter AIDS Cohort Study, a long-standing federally funded study composed largely of Caucasian men who have sex with men.

The investigators sought to estimate how much of the person-to-person variation in the rate of CD4 cell loss could be accounted for on the basis of each patient's initial viral load, in an attempt to reproduce more closely the situation that a physician would encounter in clinical practice, where a patient presents with an initial set of laboratory results and the clinician must try to predict how quickly that person's CD4 cell count will reach the danger level at which treatment for HIV becomes most critical. Current clinical practice, based on previous work from other groups, is to focus on both the current CD4 count and the viral load to estimate how rapidly a person's CD4 cell count will decrease. This approach is based on comparisons of the average rate of CD4 cell loss among groups of patients with roughly similar viral loads, which indicate that generally speaking, patients with higher viral loads will tend to experience more rapid CD4 cell loss than patients with lower viral loads. Until now, however, there had been no attempt to quantify how well this observation held when considering the estimated rate of CD4 cell loss for each individual patient.

Using sophisticated statistical modeling, the researchers found that only 4-6% of a
'"/>

Source:University Hospitals of Cleveland


Page: 1 2 3

Related biology news :

1. Bioartificial kidney under study at MCG
2. W.M. Keck Foundation funds study of friendly microbes
3. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
4. Genome-wide mouse study yields link to human leukemia
5. Clam embryo study shows pollutant mixture adversely affects nerve cell development
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Same mutation aided evolution in many fish species, Stanford study finds
8. Sequencing of marine bacterium will help study of cell communication
9. Genetically modified rice in China benefits farmers health, study finds
10. A new study examines how shared pathogens affect host populations
11. NYU study reveals how brains immune system fights viral encephalitis
Post Your Comments:
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in ... seeing a staggering demand from its licensees for highly ... revealed, is not solely coming from fitness and health ... "A wearable is only as useful as ... is the ultimate driver in long-term mass consumer adoption ...
(Date:12/5/2014)... , Dec. 4, 2014 Increased emphasis ... investments in new testing and inspection technologies. The ... rise to a range of innovative test solutions. ... of Generation Y, which is generally more inclined ... result, product development strategies of test equipment vendors ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... PITTSBURGH Nov. 9, 2007 Researchers at Childrens Hospital ... trial currently underway to study the effectiveness of oral insulin ... in people at risk for the disease. The researchers ... prevent or delay the onset of type 1 diabetes in ...
... will convene at the Institute of Ecosystem Studies ... future of biofuel production in the United States. ... biofuel experts, including Drs. David Pimentel (Cornell University), ... State)., Corn and soy-based ethanol have been touted ...
... barbecue knows that hot dogs are inexplicably packaged in different ... 10 hot dog buns. Put in ecological terms, this means ... are worthless without hot dogs to fill them. ... phosphorus or nitrogen limits plant production in most ecosystems. According ...
Cached Biology News:Children's Hospital studying drug with the potential to prevent/delay onset of type 1 diabetes 2Can plant-based ethanol save us from our fossil fuel addiction? 2At the root of nutrient limitation, ecosystems are not as different as they seem 2At the root of nutrient limitation, ecosystems are not as different as they seem 3
(Date:12/24/2014)... PARIS and NEW YORK ... data from its open-label pilot study of mazindol in ... Design, Development and Therapy in December 2014 . ... of mazindol in children with attention deficit/hyperactivity disorder" ( ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) ...
(Date:12/22/2014)... GenomeDx Biosciences today announced that a new ... genomic test for prostate cancer, was able to predict ... radical prostatectomy without adjuvant therapy. Although rapid metastasis in ... tumor genomics to identify these men who have a ... advance. The study has been published online by ...
(Date:12/19/2014)... PA (PRWEB) December 19, 2014 ... leading developer and manufacturer of needle-free injection technology, ... agreement with Immunomic Therapeutics, Inc. (“ITI”) for ITI ... device with its LAMP™ vaccine platform. , ... an exclusive Worldwide license to the Biojector®-2000 that ...
(Date:12/19/2014)... CITY, Calif. , Dec. 19, 2014 Bina ... , USA) announced today that they have been acquired ... 1,2 is a privately held company that provides ... of next generation sequencing (NGS) data for the academic ... the Roche Sequencing Unit, and will continue to focus ...
Breaking Biology Technology:Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in ... for the treatment of Alzheimer,s and other neurological ... collaboration agreement with the University California, Irvine to ... vaccine candidate to induce an immune response against ...
... Conference: May 21-24, 2012 ,Exhibition: May 22-24, 2012 ,Pennsylvania ... Medical Design and Manufacturing (MD&M) East Conference have announced ... Convention Center, May 21 - 24, 2012. The conference ... dedicated to medical design and manufacturing professionals, featuring presentations ...
... CMC Biologics is a leading contract manufacturing organization (CMO) ... process development and cGMP manufacture of ... growth factors), as well as monoclonal antibodies. CMC ... characterization capabilities, expertise in continuous perfusion systems and ...
Cached Biology Technology:Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimer's Research Group at University of California Irvine to Test First in Class Dual Target Vaccine 2Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimer's Research Group at University of California Irvine to Test First in Class Dual Target Vaccine 3Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimer's Research Group at University of California Irvine to Test First in Class Dual Target Vaccine 4MD&M East 2012 to Feature FDA and Medical Technology Development Leaders 2CMC Biologics Highlights Technical Acumen at Upcoming Conferences 2CMC Biologics Highlights Technical Acumen at Upcoming Conferences 3CMC Biologics Highlights Technical Acumen at Upcoming Conferences 4CMC Biologics Highlights Technical Acumen at Upcoming Conferences 5
... Polymerase is ideal for high-fidelity amplification ... such as cloning and mutagenesis. ... proprietary enzyme preparation containing recombinant DNA ... (3'Cut Site5' exonuclease) activity. Platinum ...
... PLAU N-term Antibody This antibody is generated ... synthetic peptide selected within aa 50~150 of ... in PBS with 0.09% (W/V) sodium azide. ... G column and eluted out with both ...
...
Human interferon-beta (IFN-beta). Recognizes amino acids 30-47 of IFN-beta. No cross-reactivity with Human IFN-alpha or IFN-gamma....
Biology Products: